Federal Register / Vol. 87, No. 12 / Wednesday, January 19, 2022 / Notices 2791 

Dated: January 12, 2022. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2022–00906 Filed 1–18–22; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

DP22–001, Real-World Effectiveness of 

Structured Lifestyle Interventions in 

Preventing Type 2 Diabetes. 

Date: March 23, 2022. 

Time: 10:30 a.m.–6:00 p.m., EDT. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

FOR FURTHER INFORMATION CONTACT: Jaya 

Raman Ph.D., Scientific Review Officer, 

National Center for Chronic Disease 

Prevention and Health Promotion, CDC, 

4770 Buford Highway, Mailstop S107–8, 

Atlanta, Georgia 30341–3717, 

Telephone: (770) 488–6511; Email: 

JRaman@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–00868 Filed 1–18–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)— 

DP22–002, Epidemiology of Lupus: 

Longitudinal Studies in PopulationBased Cohorts. 

Date: March 17, 2022. 

Time: 11:00 a.m.–6:00 p.m., EDT. 

Place: Teleconference. 

Agenda: To review and evaluate grant 

applications. 

For Further Information Contact: Jaya 

Raman, Ph.D., Scientific Review Officer, 

National Center for Chronic Disease and 

Health Promotion, CDC, 4770 Buford 

Highway, Mailstop S107–8, Atlanta, 

Georgia 30341–3717, Telephone: (770) 

488–6511, Email: JRaman@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–00867 Filed 1–18–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

[Docket No. CDC–2022–0003] 

Draft Policy Statement for Biosafety 

Level 4 (BSL–4) and Animal BSL–4 

(ABSL–4) Laboratory Verification; 

Notice of Availability 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of availability and 

comment. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC) in the 

Department of Health and Human 

Services (HHS) announces the opening 

of a docket to obtain comment on a draft 

policy statement regarding Biosafety 

Level 4 (BSL–4)/Animal Biosafety Level 

4 (ABSL–4) verification requirements. 

The policy statement, once finalized, 

will assist individuals and entities in 

verifying that the facility design 

parameters and operational procedures, 

including heating, ventilation, and air 

conditioning (HVAC) systems, in BSL– 

4 and/or ABLS–4 laboratories are 

functioning as intended to meet the 

biosafety sufficiency requirement in the 

HHS/CDC select agent regulations. 

DATES: Submit written or electronic 

comments by March 21, 2022. 

ADDRESSES: You may submit comments, 

identified by Docket No. CDC–2022– 

0003, by either of the following 

methods. 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Division of Select Agents and 

Toxins, Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, 

Mailstop H21–7, Atlanta, Georgia 30329. 

Instructions: All submissions received 

must include the Agency name and 

Docket No. CDC–2022–0003. All 

relevant comments received will be 

posted without change to http://

www.regulations.gov, including any 

personal information provided. Do not 

send comments by email. CDC does not 

accept comments by email. 

Docket Access: For access to the 

docket to read background documents 

or comments received, or to download 


jspears on DSK121TN23PROD with NOTICES1